SOAT1 and metabolic dysfunction-associated steatotic liver disease: Our in vitro experiments demonstrated that hesperetin may disrupt this vicious cycle by inhibiting IL-6-mediated STAT3 phosphorylation, thereby attenuating inflammatory signaling in the JAK-STAT axis and lipid dysregulation in the NAFLD pathway.